Immunotherapy post-surgery improves overall survival for kidney cancer
Boston – For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survival benefit from an adjuvant therapy in patients with kidney cancer.
Treatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall survival in patients with clear-cell renal-cell carcinoma (ccRCC) at high risk for recurrence, according to an analysis of results from the KEYNOTE-564 study. Pembrolizumab was associated with a 38% reduction in risk of death compared with placebo.
“We can now ...













